Hexarelinobservational1999

Low dose hexarelin and growth hormone (GH)-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults: comparison with insulin-induced hypoglycemia test.

The Journal of clinical endocrinology and metabolism

confidence

Key findings

Low-dose hexarelin+GHRH test is as sensitive as ITT for diagnosing adult GHD when appropriate cut-off limits (51.2 microg/L) are used.

View source on PubMed (PMID 10443652) ↗

Sample size
Normal: 25 (NS) + 33 + 77; GHD: 19
Population
Normal young adult volunteers and hypopituitaric adults with GH deficiency
Dosing
Hexarelin 0.25 microg/kg; GHRH 1 microg/kg; arginine for GHRH+ARG; insulin for ITT
Duration
Acute provocative testing (single/repeat sessions)
Route
intravenous
Blinding
not_reported
Controls
none
Drug class
GH secretagogue

Measured endpoints

  • GH peak response to GHRH+HEX in normal subjectsIncreasedhormonal
    not_reportedeffect: 83.6+/-4.5 microg/L
  • GH peak response to GHRH+HEX in GHD patientsDecreasedhormonal
    significanteffect: 2.6+/-0.7 microg/L
  • GH peak response to GHRH+ARG in GHD patientsDecreasedhormonal
    significanteffect: 3.6+/-1.0 microg/L
  • GH peak response to ITT in GHD patientsDecreasedhormonal
    significanteffect: 0.6+/-0.1 microg/L
  • Reproducibility of GH response to GHRH+HEXNo changehormonal
    not_reportedeffect: good intraindividual reproducibility
  • Diagnostic sensitivity of GHRH+HEX for adult GHDImprovedhormonal
    not_reportedeffect: 100% below first percentile cut-off (51.2 microg/L)
Full abstract

GH deficiency (GHD) in adults must be shown by provocative testing of GH secretion. Insulin-induced hypoglycemia (ITT) is the test of choice, and severe GHD, treated with recombinant human GH replacement, is defined by a GH peak response to ITT of less than 3 microg/L. GHRH plus arginine (ARG) is a more provocative test and is as sensitive as ITT provided that appropriate cut-off limits are assumed. GH secretagogues are a family of peptidyl and nonpeptidyl GH-releasing molecules that strongly stimulate GH secretion and, even at low doses, truly synergize with GHRH. Our aim was to verify the diagnostic reliability of the hexarelin (HEX; 0.25 microg/kg, iv) and GHRH (1 microg/kg, iv) test for the diagnosis of adult GHD. To this goal, in the present study we 1) defined the normal ranges of the GH response to GHRH+HEX in a group of normal young adult volunteers (NS; n = 25; 18 men and 7 women; age, 28.5+/-0.6 yr) and in 11 of them verified its reproducibility in a second session, and 2) compared the GH response to GHRH+HEXwith that to ITT in a group of normal subjects (n = 33; 12 men and 21 women; age, 34.1+/-1.5 yr) and hypopituitaric adults with GHD (n = 19; 10 men and 9 women; age, 39.9+/-2.2 yr; GH peak <5 microg/L after ITT). The GH response to GHRH+ARG was also evaluated in all GHD and in 77 normal subjects (40 men and 37 women; age, 28.1+/-0.6 yr). The mean GH peak after GHRH+HEX in NS was 83.6+/-4.5 microg/L; the third and first percentile limits of the normal GH response were 55.5 and 51.2 microg/L, respectively). The GH response to GHRH+HEX in NS showed good intraindividual reproducibility. In GHD the mean GH peak after GHRH+HEX (2.6+/-0.7 microg/L) was similar to that after GHRH+ARG (3.6+/-1.0 microg/L), and both were higher (P < 0.001) than that after ITT (0.6+/-0.1 microg/L); the GH responses to GHRH+HEX were positively associated with those to ITT and GHRH+ARG. Analyzing individual GH responses, 100% had severe GHD after ITT (GH peak, <3 microg/L). After GHRH+HEX all GHD had GH peaks below the third percentile limit of normality appropriate for this test (i.e. 55.5 microg/L). Thirteen of 19 (68.4%) GHD subjects had GH peaks below 3 microg/L after GHRH+HEX but all 19 (100%) had GH peaks below the first percentile limit of normality (i.e. 51.2 microg/L). The GH responses to GHRH+HEX were highly concordant with those after GHRH+ARG. In conclusion, the present results define normal limits of the GH response to stimulation with low dose HEX+GHRH in normal adults and show that this test is as sensitive as ITT for the diagnosis of adult GHD provided that appropriate cut-off limits are considered.

Research information, not medical advice. StudyKit summarizes published studies to help you understand your protocol. It does not diagnose, treat, or replace a clinician. Talk to a qualified provider before changing anything you take.